
Tamar Taddei

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5506390/publications.pdf Version: 2024-02-01



Ταμάρ Τάρρει

#	Article	IF	CITATIONS
1	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 4317-4345.	1.6	350
2	Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: AÂnationwide cohort study. PLoS Medicine, 2020, 17, e1003379.	8.4	271
3	Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology, 2019, 157, 1264-1278.e4.	1.3	252
4	Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology, 2017, 152, 1954-1964.	1.3	185
5	The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. American Journal of Hematology, 2009, 84, 208-214.	4.1	146
6	Incidence and Mortality of Acuteâ€onâ€Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis. Hepatology, 2019, 69, 2150-2163.	7.3	139
7	Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database. Clinical Gastroenterology and Hepatology, 2015, 13, 2333-2341.e6.	4.4	98
8	Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. Gastroenterology, 2019, 156, 1693-1706.e12.	1.3	98
9	Gaucher Disease and Malignancy: A Model for Cancer Pathogenesis in an Inborn Error of Metabolism. Critical Reviews in Oncogenesis, 2013, 18, 235-246.	0.4	96
10	Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology, 2017, 65, 864-874.	7.3	94
11	Risk Prediction Models for Postâ€Operative Mortality in Patients With Cirrhosis. Hepatology, 2021, 73, 204-218.	7.3	83
12	Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. Journal of Clinical Oncology, 2017, 35, 3575-3581.	1.6	76
13	Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. JAMA Internal Medicine, 2021, 181, 1306.	5.1	63
14	Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation. Hepatology, 2021, 73, 219-232.	7.3	59
15	Postvaccination COVIDâ€19 infection is associated with reduced mortality in patients with cirrhosis. Hepatology, 2022, 76, 126-138.	7.3	49
16	High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. Journal of Inherited Metabolic Disease, 2010, 33, 291-300.	3.6	47
17	Pseudocirrhosis in a pancreatic cancer patient with liver metastases: A case report of complete resolution of pseudocirrhosis with an early recognition and management. World Journal of Gastroenterology, 2008, 14, 1622.	3.3	43
18	Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States. Clinical Gastroenterology and Hepatology, 2018, 16, 106-114.e5.	4.4	38

#	Article	IF	CITATIONS
19	Impact of body mass index on graft failure and overall survival following liver transplant*. Clinical Transplantation, 2004, 18, 634-637.	1.6	36
20	Male Sex Is Associated With Higher Rates of Liverâ€Related Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology, 2021, 74, 879-891.	7.3	36
21	Quality Measures, All ause Mortality, and Health Care Use in a National Cohort of Veterans With Cirrhosis. Hepatology, 2019, 70, 2062-2074.	7.3	35
22	Grade 1 Acute on Chronic Liver Failure Is a Predictor for Subsequent Grade 3 Failure. Hepatology, 2020, 72, 230-239.	7.3	35
23	Factors Associated With Access to and Receipt of Liver Transplantation in Veterans With End-stage Liver Disease. JAMA Internal Medicine, 2021, 181, 949.	5.1	35
24	Macrotrabecular Hepatocellular Carcinoma. American Journal of Surgical Pathology, 2019, 43, 943-948.	3.7	34
25	Palliative care in decompensated cirrhosis: A review. Liver International, 2018, 38, 768-775.	3.9	33
26	Introducing Palliative Care within the Treatment of End-Stage Liver Disease: The Study Protocol of a Cluster Randomized Controlled Trial. Journal of Palliative Medicine, 2019, 22, S-34-S-43.	1.1	33
27	SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites. Clinical Liver Disease, 2018, 11, 141-144.	2.1	31
28	Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis. Clinical Gastroenterology and Hepatology, 2021, 19, 2148-2160.e14.	4.4	31
29	Inherited metabolic disease of the liver. Current Opinion in Gastroenterology, 2008, 24, 278-286.	2.3	29
30	Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology Communications, 2021, 5, 1426-1436.	4.3	29
31	Comparing Child-Pugh, MELD, and FIB-4 to Predict Clinical Outcomes in Hepatitis C Virus-Infected Persons: Results From ERCHIVES. Clinical Infectious Diseases, 2017, 65, 64-72.	5.8	28
32	AGA Clinical Practice Update on Palliative Care Management in Cirrhosis: Expert Review. Clinical Gastroenterology and Hepatology, 2021, 19, 646-656.e3.	4.4	28
33	Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis. American Journal of Gastroenterology, 2021, 116, 1913-1923.	0.4	28
34	Coronavirus Disease 2019 Vaccination Is Associated With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Death in Liver Transplant Recipients. Gastroenterology, 2022, 162, 645-647.e2.	1.3	27
35	Systemic Therapy in Hepatocellular Carcinoma. Clinics in Liver Disease, 2011, 15, 423-441.	2.1	26
36	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology, 2022, 75, 1289-1299.	7.3	26

#	Article	IF	CITATIONS
37	Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Digestive Diseases and Sciences, 2019, 64, 1016-1029.	2.3	25
38	Risk prediction scores for acute on chronic liver failure development and mortality. Liver International, 2020, 40, 1159-1167.	3.9	22
39	Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. Journal of Hepatology, 2022, 76, 1100-1108.	3.7	22
40	The Association Between Proton Pump Inhibitor Exposure and Key Liver-Related Outcomes in Patients With Cirrhosis: A Veterans Affairs Cohort Study. Gastroenterology, 2022, 163, 257-269.e6.	1.3	22
41	HIV, Aging, and Viral Coinfections: Taking the Long View. Current HIV/AIDS Reports, 2016, 13, 269-278.	3.1	21
42	The Predictive Role of Model for Endâ€Stage Liver Disease–Lactate and Lactate Clearance for Inâ€Hospital Mortality Among a National Cirrhosis Cohort. Liver Transplantation, 2021, 27, 177-189.	2.4	21
43	Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case–control study. Cancer Causes and Control, 2020, 31, 321-332.	1.8	20
44	Patient Frailty Is Independently Associated With the Risk of Hospitalization for Acuteâ€onâ€Chronic Liver Failure. Liver Transplantation, 2021, 27, 16-26.	2.4	20
45	Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation. Transplantation Proceedings, 2011, 43, 905-908.	0.6	19
46	Recalibrating the Child–Turcotte–Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with Cirrhosis. Digestive Diseases and Sciences, 2016, 61, 3309-3320.	2.3	19
47	Preâ€ŧransplant alphaâ€fetoprotein is associated with postâ€ŧransplant hepatocellular carcinoma recurrence mortality. Clinical Transplantation, 2019, 33, e13634.	1.6	19
48	Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. Journal of General Internal Medicine, 2020, 35, 2025-2034.	2.6	19
49	Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus. Medical Care, 2019, 57, 279-285.	2.4	18
50	Therapeutic Strategies for Hepatocellular Carcinoma: New Advances and Challenges. Current Treatment Options in Gastroenterology, 2015, 13, 219-234.	0.8	17
51	Changes in Hepatocellular Carcinoma Surveillance and Risk Factors for Noncompletion in the Veterans Health Administration Cohort During the Coronavirus Disease 2019 Pandemic. Gastroenterology, 2021, 160, 2162-2164.e3.	1.3	17
52	Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology, 2022, 304, 228-237.	7.3	17
53	Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. British Journal of Cancer, 2021, 124, 407-413.	6.4	15
54	Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma. Transplantation, 2020, 104, 104-112.	1.0	14

#	Article	IF	CITATIONS
55	Comparison of Natural Language Processing and Manual Coding for the Identification of Cross-Sectional Imaging Reports Suspicious for Lung Cancer. JCO Clinical Cancer Informatics, 2018, 2, 1-7.	2.1	13
56	SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemporary Clinical Trials, 2021, 104, 106367.	1.8	13
57	Risk Prediction Models for Postoperative Decompensation and Infection in Patients With Cirrhosis: A Veterans Affairs Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, e1121-e1134.	4.4	12
58	Oral Cyanobacteria and Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 221-229.	2.5	12
59	Balancing quality with quantity: The role of palliative care in managing decompensated cirrhosis. Hepatology, 2016, 64, 1014-1016.	7.3	11
60	Implementation of a Population-Based Cirrhosis Identification and Management System. Clinical Gastroenterology and Hepatology, 2018, 16, 1182-1186.e2.	4.4	11
61	Hepatocellular Carcinoma Outcome Is Predicted by Expression of Neuronal Calcium Sensor 1. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1091-1100.	2.5	11
62	The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance. Cancer Medicine, 2019, 8, 5948-5958.	2.8	11
63	Frailty Is a Risk Factor for Postoperative Mortality in Patients With Cirrhosis Undergoing Diverse Major Surgeries. Liver Transplantation, 2021, 27, 699-710.	2.4	11
64	Comparison of infectionâ€induced and vaccineâ€induced immunity against COVIDâ€19 in patients with cirrhosis. Hepatology, 2023, 77, 186-196.	7.3	11
65	Models for acute on chronic liver failure development and mortality in a veterans affairs cohort. Hepatology International, 2020, 14, 587-596.	4.2	10
66	Impact of <scp>SGLT2</scp> inhibitors in comparison with <scp>DPP4</scp> inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes, Obesity and Metabolism, 2021, 23, 2402-2408.	4.4	10
67	Palliative Care Always: Hepatology—Virtual Primary Palliative Care Training for Hepatologists. Hepatology Communications, 2022, 6, 920-930.	4.3	9
68	Combined Liver Kidney Transplantation: Critical Analysis of a Single-Center Experience. Transplantation Proceedings, 2011, 43, 901-904.	0.6	8
69	Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people. BMC Gastroenterology, 2019, 19, 52.	2.0	8
70	Fibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation. Journal of Clinical Pathology, 2021, 74, 31-35.	2.0	8
71	Evaluation Within 30 Days of Referral for Liver Transplantation is Associated with Reduced Mortality: A Multicenter Analysis of Patients Referred Within the VA Health System. Transplantation, 2022, 106, 72-84.	1.0	8
72	A Multidisciplinary Approach. Journal of Clinical Gastroenterology, 2013, 47, S27-S29.	2.2	7

#	Article	IF	CITATIONS
73	New frontier in liver cancer treatment: Oncolytic viral therapy. Hepatology, 2014, 59, 343-346.	7.3	7
74	Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination. Journal of Hepatology, 2017, 67, 186-191.	3.7	7
75	Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. Journal of Vascular and Interventional Radiology, 2018, 29, 540-549.e4.	O.5	7
76	<scp>SGLT2</scp> inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. Journal of Diabetes, 2021, 13, 265-269.	1.8	7
77	Inpatient Gastroenterology Consultation and Outcomes of Cirrhosis-Related Hospitalizations in Two Large National Cohorts. Digestive Diseases and Sciences, 2022, 67, 2094-2104.	2.3	7
78	Rates of decompensation, hepatocellular carcinoma and mortality in AMAâ€negative primary biliary cholangitis cirrhosis. Liver International, 2022, 42, 384-393.	3.9	7
79	MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features. Journal of Vascular and Interventional Radiology, 2022, 33, 814-824.e3.	0.5	7
80	Increased T-Cell Sinusoidal Lymphocytosis in Liver Biopsies in Patients With Chronic Hepatitis C and Mixed Cryoglobulinemia. American Journal of Gastroenterology, 2008, 103, 705-711.	0.4	6
81	Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. PLoS ONE, 2019, 14, e0221614.	2.5	6
82	HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas. Archives of Pathology and Laboratory Medicine, 2022, 146, 220-226.	2.5	6
83	Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal of Hepatology, 2021, 75, 1312-1322.	3.7	6
84	Emphysematous Cholecystitis Resulting in Secondary Biliary Cirrhosis: A Rare Complication of Endoscopic Retrograde Cholangiopancreatography. ACG Case Reports Journal, 2013, 1, 51-54.	0.4	6
85	Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection. Archives of Pathology and Laboratory Medicine, 2021, 145, 419-427.	2.5	6
86	Hepatic Venous Pressure Gradient (HVPG), Serum Sodium (SNa), and Model of End-stage Liver Disease Score (MELD). Journal of Clinical Gastroenterology, 2007, 41, 641-643.	2.2	5
87	Race Adjustment in eGFR Equations Does Not Improve Estimation of Acute Kidney Injury Events in Patients with Cirrhosis. Digestive Diseases and Sciences, 2022, 67, 1399-1408.	2.3	5
88	Reply:. Hepatology, 2019, 70, 2236-2238.	7.3	4
89	Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 71-78.	2.5	4
90	Development and Implementation of Multidisciplinary Liver Tumor Boards in the Veterans Affairs Health Care System: A 10-Year Experience. Cancers, 2021, 13, 4849.	3.7	4

#	Article	IF	CITATIONS
91	Hepatocellular Carcinoma. American Journal of Clinical Pathology, 2022, 157, 305-313.	0.7	4
92	Necrotizing Pancreatitis Complicated by Fistula and Upper Gastrointestinal Hemorrhage. Clinical Gastroenterology and Hepatology, 2011, 9, e66-e67.	4.4	3
93	Impact of Neoadjuvant Chemotherapy and Pretreatment Biliary Drainage for Pancreatic Head Ductal Adenocarcinoma. Digestive Diseases and Sciences, 2021, , 1.	2.3	3
94	EMR-linked cancer trackerÂfacilitates lung and liver cancer care Journal of Clinical Oncology, 2012, 30, 77-77.	1.6	3
95	Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma. Medicine (United States), 2018, 97, e9757.	1.0	2
96	Aspirin Use and Risk of Hepatocellular Carcinoma in Hepatitis B. JAMA Internal Medicine, 2019, 179, 640.	5.1	2
97	A Clinical Decision Support System for Monitoring Post-Colonoscopy Patient Follow-Up and Scheduling. AMIA Summits on Translational Science Proceedings, 2017, 2017, 295-301.	0.4	2
98	When should a hepatitis Câ€positive ESRD patient receive a renal transplant?. Seminars in Dialysis, 2011, 24, 438-439.	1.3	1
99	INTRODUCTION. Journal of Clinical Gastroenterology, 2013, 47, S1.	2.2	1
100	Learning from the Melbourne experience: How reliable are cancer registry data for hepatocellular carcinoma?. Hepatology, 2016, 63, 1078-1079.	7.3	1
101	Assessing the Impact of Referral on Multidisciplinary Tumor Board Outcomes in Patients With Hepatocellular Carcinoma. Journal of the American College of Radiology, 2020, 17, 1636-1643.	1.8	1
102	Palliative Care in Cirrhosis: Beyond Misconceptions. Current Treatment Options in Gastroenterology, 2020, 18, 245-254.	0.8	1
103	Using a European Value-Based Medicine Approach to Evaluate Hepatocellular Carcinoma Care at a US Tertiary Care Center Journal of Clinical Oncology, 2015, 33, e15118-e15118.	1.6	1
104	Clinical Research Training During Gastroenterology Fellowship. Digestive Diseases and Sciences, 2022, 67, 1097.	2.3	1
105	Diagnostic Momentum in Acute Liver Injury: an Exercise in Clinical Reasoning. Journal of General Internal Medicine, 2022, 37, 2861-2865.	2.6	1
106	Pursuing a Gastroenterology Fellowship as a Foreign Medical Graduate. Digestive Diseases and Sciences, 2017, 62, 1852-1854.	2.3	0
107	Primary Liver Tumors Other than Hepatocellular Carcinoma: Clinical and Molecular Pearls. Current Hepatology Reports, 2018, 17, 412-424.	0.9	0
108	The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma. Cancer Medicine, 2021, 10, 5395-5404.	2.8	0

Tamar Taddei

#	Article	IF	CITATIONS
109	REPLY:. Hepatology, 2021, 74, 2308-2308.	7.3	0
110	REPLY:. Hepatology, 2021, 74, 2322-2323.	7.3	0
111	Protective altruistic phlebotomy: hereditary haemochromatosis presenting as hepatocellular carcinoma in a non-cirrhotic 83-year-old man. BMJ Case Reports, 2016, 2016, bcr2016216649.	0.5	0
112	The effect of socioeconomic factors on the outcome of hepatocellular carcinoma Journal of Clinical Oncology, 2018, 36, 466-466.	1.6	0
113	Effect of outside referrals to a tertiary care liver tumor board on diagnostic testing and initial curative therapy Journal of Clinical Oncology, 2018, 36, 259-259.	1.6	0
114	An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenib Journal of Clinical Oncology, 2020, 38, 12049-12049.	1.6	0
115	Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 530-534.	2.1	0
116	Effect of a cancer tracking system on timeliness of liver cancer care at a Veteran's Hospital Journal of Clinical Oncology, 2022, 40, 406-406.	1.6	0
117	Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?― Journal of Hepatology, 2022, , .	3.7	0
118	Title is missing!. , 2020, 17, e1003379.		0
119	Title is missing!. , 2020, 17, e1003379.		0
120	Title is missing!. , 2020, 17, e1003379.		0
121	Title is missing!. , 2020, 17, e1003379.		Ο